Collaboration on lead optimisation
UK companies Synaptica and Maybridge have signed a research agreement, whereby Maybridge will undertake a medicinal chemistry lead optimisation programme for one of Synaptica's therapeutic programmes. Under the terms of the agreement, Maybridge's scientists will work closely with a team at Synaptica to generate a series of candidates for progression into Synaptica's development pipeline. The agreement provides for fee-for-service chemistry-based drug discovery and development, and contract services.
Synaptica is a biotechnology company developing novel therapeutics for the treatment of neurodegenerative and other neurological disorders. Maybridge is a producer of organic compounds used in screening and lead generation and optimisation.
Dr Mike Capaldi, ceo at Synaptica, commented: 'This agreement is very exciting. Maybridge has impressive expertise in medicinal chemistry and for the synthesis of biologically active compounds. This is a powerful partnership for developing our pipeline.'